- |||||||||| OVM-200 / Dx&Vx
Turning the tumour-associated antigen survivin into a neoantigen-like cancer therapeutic vaccine (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1678;
P1
Trial Registration First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine ClinicalTrials.gov ID NCT05104515 Sponsor Oxford Vacmedix UK Ltd...You should not expect to receive anything further relating to this application. Please now work with participating NHS organisations to confirm capacity and capability, in line with the instructions provided in the 'Information to support study set up' section towards the end of this letter.Download figure Open in new tab Download powerpoint Abstract 153 Figure 1 Patients groupingDownload figure Open in new tab Download powerpoint Abstract 153 Figure 2 T cell activityDownload figure Open in new tab Download powerpoint Abstract 153 Figure 3 Antibody levelDownload figure Open in new tab Download powerpoint Abstract 153 Figure 4 Cancer Biomarker
- |||||||||| OVM-200 / Dx&Vx
Trial completion date, Trial primary completion date: OVM-200-100: First-in-human Study of OVM-200 As a Therapeutic Cancer Vaccine (clinicaltrials.gov) - Apr 5, 2024
P1, N=36, Recruiting,
Please now work with participating NHS organisations to confirm capacity and capability, in line with the instructions provided in the 'Information to support study set up' section towards the end of this letter.Download figure Open in new tab Download powerpoint Abstract 153 Figure 1 Patients groupingDownload figure Open in new tab Download powerpoint Abstract 153 Figure 2 T cell activityDownload figure Open in new tab Download powerpoint Abstract 153 Figure 3 Antibody levelDownload figure Open in new tab Download powerpoint Abstract 153 Figure 4 Cancer Biomarker Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| OVM-200 / Dx&Vx
Trial completion date, Trial primary completion date: OVM-200-100: First-in-human Study of OVM-200 As a Therapeutic Cancer Vaccine (clinicaltrials.gov) - Mar 22, 2023
P1, N=36, Recruiting,
Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Jan 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
|
